Japan’s general trading houses are steadily becoming a force to be reckoned with in the pharmaceutical industry — and not…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Astellas CFO Outlines Cost Cuts, Licensing Push as Xtandi Nears Patent Cliff
August 25, 2025
-
REGULATORY Novartis’ Radioligand Therapy, More Meds Inch Closer to Japan Approval with Panel OK
August 25, 2025
-
REGULATORY PMDA’s “Early Considerations” Start to Pay Off with Faster Reviews
August 22, 2025
-
REGULATORY Japan Mulls Preferential R&D Tax Credits for Strategic Technologies in FY2026 Reform Talks
August 22, 2025
-
ORGANIZATION Hemp Cannabinoid Consortium Draws 40 Inquiries from Industry and Academia
August 22, 2025
-
BUSINESS Linepharma Japan Eyes Ophthalmology as Second Pillar to Women’s Health
August 22, 2025
-
REGULATORY AMED to Put Practicality First in Project Selection: Ecosystem Coordinator
August 21, 2025
-
BUSINESS Itochu Launches J-STEP to Help Overseas Drug Makers Tackle Japan’s “Drug Loss”
August 21, 2025
-
BUSINESS Alloy Japan Looks to Turn iCAR-T into Shared Infrastructure, IND Filing Slated for 2026
August 20, 2025
-
BUSINESS Keytruda Retains Top Spot in Japan Drug Market in April-June: IQVIA
August 20, 2025
-
REGULATORY Japan Weighs Legal Framework for Pharmaceutical Data Protection; JPMA Sees Opportunity for Reform
August 19, 2025
-
REGULATORY Japan Approves First SGLT2 Generics, 12 Firms Pile into Vimpat Ahead of December Listing
August 18, 2025
-
REGULATORY Novartis’ Radioligand Therapy, Other New Meds Up for Japan Panel Review on Aug. 22
August 12, 2025
-
REGULATORY Japan Nears Approval for 1st Biosimilars of Actemra, Simponi, and Ranmark
August 12, 2025
-
REGULATORY Japan Approves FY2026 Budget Guidelines, Natural Increase at 400 Billion Yen
August 12, 2025
-
BUSINESS Ashraf Al-Ouf Named President of Bayer Yakuhin and Bayer Holding in Japan
August 8, 2025
-
REGULATORY Public-Private Council WG to Focus on Innovation Evaluation for FY2026 Reform: Official
August 8, 2025
-
BUSINESS Sumitomo Eyes Conditional Nod for iPS Cell Therapy for Parkinson’s in FY2025
August 8, 2025
-
BUSINESS PeptiDream Probes Ex-COO over Unauthorized Provision of Reagents to Academia
August 8, 2025
-
REGULATORY Industry Urges “Objective Review First” for CEA Reform; Payers Push for Expansion
August 7, 2025
ページ
A public-private council report outlining industry views on Japan’s drug pricing systems drew little discussion at a meeting of the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…